バイエルのインスタグラム(bayerofficial) - 8月27日 20時30分
Curing and preventing cancer is one of the main focus areas of @leapsbybayer.
Thus, we’re excited to support the development of next-generation cancer therapies that promise to address previously incurable cancers.
Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD 55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer, and Northpond Ventures.
[BIHAKUEN]UVシールド(UVShield)
>> 飲む日焼け止め!「UVシールド」を購入する
505
17
2020/8/27